Ignacio Gil‐Bazo

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M. Duruisseaux, Anna Martínez‐Cardús, María Eréndira Calleja-Cervantes et al. · The Lancet Respiratory Medicine · 2018 · 222 citations · Full text

Medicine, Oncology, Epigenetics +16

Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway

Simona Taverna, Marzia Pucci, Marco Giallombardo et al. · Scientific Reports · 2017 · 157 citations · Full text

Medicine, Cell Biology, Oncology +17

Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

Daniel Ajona, Sergio Ortiz‐Espinosa, Teresa Lozano et al. · Nature Cancer · 2020 · 143 citations

Medicine, Cancer Biology, Oncology +16

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

María E. Rodríguez-Ruiz, José Luis Perez‐Gracia, Inmaculada Rodríguez et al. · Annals of Oncology · 2018 · 142 citations · Full text

Medicine, Immunology, Oncology +17